Abstract: An apparatus for adjusting a seat of a vehicle includes a seat back frame, a cushion frame that is moved forward and backward by a motor driving unit, a cushion hinge part connecting the seat back frame and the cushion frame and rotating according to the movement of the cushion frame to adjust the angle of the seat back frame, and a seat back hinge part connecting the seat back frame and the vehicle body and rotating according to the movement of the seat back frame.

Abstract: A railess variable seatback type rear seat includes: a linear movement device configured to convert a rotation of a motor into a linear movement; a sliding movement device configured to convert the linear movement into a sliding movement in which a seat cushion is pushed forward or backward; and a reclining angle change device configured to convert the sliding movement into a reclining movement, and to fold a seatback, which is connected to the seat cushion, forward or to recline the seatback backward.

Abstract: An apparatus for controlling a discharge pressure of a fluid includes: a pump configured to suck the fluid through an inlet or to discharge the sucked fluid through an outlet; a distributor connected to the pump and to an injection nozzle provided by a sensor and configured to distribute the fluid discharged from the pump to the sensor; and a controller. The controller is configured to control the pump to operate selectively in accordance with detection of contamination of the sensor and to control operation of the distributor to be forcibly delayed during operation of the pump such that the fluid distributed to the sensor, when detected as being contaminated, is controlled to reach a selected required discharge pressure of different required discharge pressures selected in accordance with water amount information and a degree of contamination of the sensor.

Abstract: A thin film transistor array substrate including a substrate including an active area and a non-active area, and a first thin film transistor disposed on the substrate while including a first oxide semiconductor pattern, a first gate electrode overlapping with the first oxide semiconductor pattern, a first gate insulating layer interposed between the first oxide semiconductor pattern and the first gate electrode, a first source electrode and a first drain electrode disposed on and connected to the first oxide semiconductor pattern, and a first light shielding pattern disposed under the first oxide semiconductor pattern and electrically connected to one of the first source electrode and the first drain electrodes. The first gate electrode includes a first portion maintaining a first parasitic capacitance and a second portion maintaining a second parasitic capacitance smaller than the first parasitic capacitance, together with the first oxide semiconductor pattern.

Abstract: A super-steep switching device and an inverter device using the same are disclosed. The super-steep switching device includes a semiconductor channel disposed on a substrate and made of a semiconductor material having impact ionization characteristic; a source electrode and a drain electrode in contact with the semiconductor channel, wherein the source electrode and the drain electrode are disposed on the substrate and are spaced apart from each other; and a gate electrode disposed on the semiconductor channel so as to overlap only a portion of the semiconductor channel, wherein a top surface of the semiconductor channel includes a first area overlapping the gate electrode, and a second area non-overlapping the gate electrode, wherein a ratio of a length of the first area and a length of the second area is in a range of 1:0.1 to 0.4.

Abstract: The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.

Abstract: The present invention relates to a melittin-anticancer drug conjugate in which melittin and an anticancer drug are conjugated, and to a method of preparing a melittin-anticancer drug conjugate by connecting melittin and an anticancer drug. A conjugate of the present invention is an anticancer material for targeting M2-type tumor-associated macrophages (TAM) and exhibits an excellent effect of selectively selecting M2-type tumor-associated macrophages (TAM), and thus may be used for a use of drug delivery for targeting M2-type tumor-associated macrophages.

Abstract: The present invention relates to: a method for preparing a stem cell culture solution which contains growth factors and cytokines and is obtained by culturing, in a serum-free medium, mesenchymal stem cells cultured in a medium containing human platelet lysates (hPLs); and a cosmetic composition using the stem cell culture solution. When the method for preparing a mesenchymal stem cell culture solution obtained from mesenchymal stem cells cultured in an hPL-containing medium is used, it is possible to obtain a mesenchymal stem cell culture solution which has a higher amount of cytokines and growth factors than that of a mesenchymal stem cell culture solution obtained from mesenchymal stem cells cultured in an FBS-containing medium, and has excellent efficacy in the promotion of human dermal fibroblast proliferation, collagen synthesis, elastin synthesis, inhibition of melanin synthesis, and hair growth.

Abstract: The present invention relates to a melittin-anticancer drug conjugate in which melittin and an anticancer drug are conjugated, and to a method of preparing a melittin-anticancer drug conjugate by connecting melittin and an anticancer drug. A conjugate of the present invention is an anticancer material for targeting M2-type tumor-associated macrophages (TAM) and exhibits an excellent effect of selectively selecting M2-type tumor-associated macrophages (TAM), and thus may be used for a use of drug delivery for targeting M2-type tumor-associated macrophages.

Abstract: The present invention relates to a composition including melittin as an active ingredient for removing an M2-type tumor-associated macrophage (TAM), and more specifically, the present invention relates to a composition exhibiting an effect of selectively suppressing only M2-type tumor-associated macrophages among tumor-associated macrophages. The composition according to the present invention only suppresses M2-type tumor-associated macrophages without affecting M1-type tumor-associated macrophages or cancer cells, thus exhibiting anti-cancer and metastasis suppressing effects by blocking angiogenesis through control of the microenvironment of cancer cells, while reducing the side-effects of existing anti-cancer effects.

Abstract: The present invention relates to a cell therapy method for treating neurodegenerative diseases, which includes administering a therapeutically effective amount of a regulatory T cell to an individual in need thereof. The regulatory T cell may be an amyloid-beta specific regulatory T cell induced by administering amyloid-beta peptide and bee venom phospholipase A2 (bvPLA2).